Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

被引：0
|
作者：
McGregor, Bradley Alexander
Wang, Xin Victoria
Hamnvik, Ole-Petter R.
Cheung, Yee Ming
Wei, Xiao X.
Ravi, Praful
Fichorova, Raina N.
Sweeney, Christopher
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
    Rezazadeh, Arash
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kapur, Shivani
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.
    Gratzke, Christian
    Burgents, Joseph E.
    Niu, Cuizhen
    Poehlein, Christian Heinrich
    Drak, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Tz, Melanie Go Spacing Diaeresis
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Unterrainer, Lena
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
    Gratzke, Christian
    Niu Cuizhen
    Poehlein, Christian Heinrich
    Burgents, Joseph E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
    Saad, F.
    Hussain, M.
    Tombal, B.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Boegemann, M.
    Tutrone, R.
    Littleton, N.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S964 - S964
  • [27] Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
    Park, Dong Jin
    Kwon, Tae Gyun
    Park, Jae Young
    Joung, Jae Young
    Ha, Hong Koo
    Jeon, Seong Soo
    Hong, Sung-Hoo
    Park, Sungchan
    Lee, Seung Hwan
    Cho, Jin Seon
    Park, Sung-Woo
    Kwon, Se Yun
    Jo, Jung Ki
    Park, Hong Seok
    Lee, Sang-Cheol
    Kwon, Dong Deuk
    Kim, Sun Il
    Park, Sang Hyun
    Kim, Soodong
    Jeong, Chang Wook
    Kwak, Cheol
    Choi, Seock Hwan
    WORLD JOURNAL OF MENS HEALTH, 2024, 42 (03): : 620 - 629
  • [28] Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS
    Tombal, B.
    Smith, M. R.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Kapur, S.
    Zhang, W.
    Ploeger, B.
    Li, R.
    Kuss, I.
    Zieschang, C.
    Wittemer-Rump, S.
    Rezazadeh, Kalebasty A.
    EUROPEAN UROLOGY, 2023, 83
  • [29] Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy plus androgen deprivation therapy (ADT)
    Duran, M. A. Climent
    Mellado, B.
    Rodriguez, J. M. Piulats
    Lopez, L. Heras
    Juan, M. J.
    Saez, M. I.
    Reig, O.
    Montesa, A.
    Suarez, J. F.
    Hajianfar, R.
    Ribal, M. J.
    Rubio, J.
    Castells, M.
    Villatoro, R.
    Sandiego, S.
    Hidalgo, D. Olmos
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY
    Shore, Neal D.
    Crawford, E. David
    Szmulewitz, Russell Z.
    Petrylak, Daniel
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Baron, Benoit
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF UROLOGY, 2020, 203 : E249 - E250
12345